In fiscal 2026, which ended Mar 31, 2026, PetMed Express, Inc. reported revenue of $179.0 million, down 21.1% from the year before. It recorded a net loss of $57.3 million. The operating loss came to $58.7 million, an operating margin of -32.8%. Diluted earnings per share were -$2.74. Over the twelve months ended Jun 30, 2026, revenue was $168.9 million and the net loss was $29.3 million. Across the 9 fiscal years shown, revenue shrank from $273.8 million in fiscal 2018 to $179.0 million in fiscal 2026, about 5.2% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jun 30, 2026
|
FY 2026
Mar 31, 2026
|
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
FY 2021
Mar 31, 2021
|
FY 2020
Mar 31, 2020
|
FY 2019
Mar 31, 2019
|
FY 2018
Mar 31, 2018
|
FY 2017
Mar 31, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
169
-20.3%
|
179
-21.1%
|
227
-19.2%
|
281
+9.5%
|
257
-5.8%
|
272
-10.3%
|
304
+6.8%
|
284
+0.2%
|
283
+3.5%
|
274
|
—
|
| Cost of revenue |
—
|
—
|
158
-16.6%
|
189
+10.7%
|
171
-12.4%
|
195
-10.9%
|
219
+8.1%
|
203
+7.9%
|
188
+6.9%
|
176
+3.6%
|
170
+7.2%
|
| Gross profit |
47
-26.9%
|
50
-27.4%
|
69
-18.4%
|
85
+10.8%
|
77
-0.6%
|
77
-8.7%
|
84
+3.8%
|
81
-14.8%
|
95
-2.5%
|
98
+23.3%
|
79
+4.0%
|
| Selling, general and administrative |
49
+4.8%
|
51
+31.3%
|
39
-30.0%
|
55
+32.4%
|
42
+34.1%
|
31
+4.7%
|
30
+17.6%
|
25
+2.0%
|
25
+2.0%
|
24
+6.5%
|
23
+7.0%
|
| Operating income |
-31
+23.2%
|
-59
-3734.8%
|
-2
+81.3%
|
-8
-234.9%
|
6
-75.1%
|
24
-20.4%
|
31
-1.4%
|
31
-32.9%
|
46
-11.4%
|
52
+39.1%
|
37
+15.7%
|
| Other income (expense) |
1
+135.1%
|
1
+39.3%
|
1
-50.1%
|
2
+35.5%
|
1
+1427.6%
|
-0
-125.1%
|
0
-85.6%
|
3
-1.1%
|
3
+78.3%
|
2
+274.8%
|
0
+146.4%
|
| Pretax income |
-29
+25.6%
|
-57
-9671.6%
|
-1
+90.6%
|
-6
-184.3%
|
7
-69.2%
|
24
-21.9%
|
31
-8.7%
|
34
-31.0%
|
49
-8.7%
|
54
+41.8%
|
38
+16.4%
|
| Income tax |
-0
-101.5%
|
-0
-101.3%
|
6
+377.2%
|
1
-48.3%
|
2
-57.9%
|
5
-22.2%
|
7
-12.6%
|
8
-29.3%
|
11
-31.0%
|
17
+17.0%
|
14
+17.5%
|
| Net income |
-29
+33.7%
|
-57
-813.5%
|
-6
+16.0%
|
-7
-245.2%
|
5
-72.5%
|
19
-21.8%
|
24
-7.5%
|
26
-31.5%
|
38
+1.2%
|
37
+56.5%
|
24
+15.8%
|
| Basic EPS |
-1.38
+35.3%
|
-2.74
-813.3%
|
-0.30
+18.9%
|
-0.37
-248.0%
|
0.25
-73.1%
|
0.93
-21.8%
|
1.19
-7.8%
|
1.29
-29.9%
|
1.84
+0.5%
|
1.83
+55.1%
|
1.18
+15.7%
|
| Diluted EPS |
-1.38
+35.6%
|
-2.74
-813.3%
|
-0.30
+18.9%
|
-0.37
-248.0%
|
0.25
-72.8%
|
0.92
-22.7%
|
1.19
-7.8%
|
1.29
-29.9%
|
1.84
+1.1%
|
1.82
+55.6%
|
1.17
+14.7%
|
| Weighted average shares, basic |
21
+2.4%
|
21
+1.6%
|
21
+1.0%
|
20
+0.6%
|
20
+0.5%
|
20
+0.6%
|
20
+0.1%
|
20
-2.1%
|
20
+0.6%
|
20
+0.6%
|
20
+0.5%
|
| Weighted average shares, diluted |
21
+2.9%
|
21
+1.6%
|
21
+1.0%
|
20
+0.3%
|
20
-0.1%
|
20
+1.2%
|
20
+0.3%
|
20
-2.1%
|
20
+0.3%
|
20
+0.3%
|
20
+0.6%
|
| Other measures | |||||||||||
| Depreciation and amortization |
9
+21.7%
|
9
+33.4%
|
7
-0.2%
|
7
+101.6%
|
4
+29.6%
|
3
+11.2%
|
2
+7.5%
|
2
+1.4%
|
2
+4.7%
|
2
+55.3%
|
1
+77.8%
|
| EBITDA |
-22
+33.7%
|
-49
-994.6%
|
6
+598.1%
|
-1
-111.6%
|
10
-64.6%
|
27
-18.1%
|
33
-0.8%
|
33
-31.3%
|
48
-10.8%
|
54
+39.7%
|
39
+17.2%
|
| Margins | |||||||||||
| Gross margin |
27.92%
|
28.05%
|
30.46%
|
30.16%
|
29.82%
|
28.26%
|
27.77%
|
28.60%
|
33.63%
|
35.72%
|
—
|
| Operating margin |
-18.22%
|
-32.77%
|
-0.67%
|
-2.90%
|
2.36%
|
8.92%
|
10.06%
|
10.90%
|
16.29%
|
19.04%
|
—
|
| Pretax margin |
-17.38%
|
-32.04%
|
-0.26%
|
-2.23%
|
2.90%
|
8.88%
|
10.19%
|
11.93%
|
17.33%
|
19.65%
|
—
|
| Profit margin |
-17.34%
|
-32.00%
|
-2.76%
|
-2.66%
|
2.00%
|
6.87%
|
7.88%
|
9.10%
|
13.32%
|
13.62%
|
—
|
| EBITDA margin |
-12.75%
|
-27.53%
|
2.43%
|
-0.39%
|
3.72%
|
9.91%
|
10.86%
|
11.70%
|
17.08%
|
19.82%
|
—
|
| Effective tax rate |
—
|
—
|
—
|
—
|
30.96%
|
22.61%
|
22.72%
|
23.73%
|
23.17%
|
30.69%
|
37.19%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Retail-Drug Stores and Proprietary Stores (SIC 5912)
- Listed as
- PETS (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- FL
- Headquarters
- Delray Beach, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1040130
Other Retail-Drug Stores and Proprietary Stores companies
- CVS HEALTH Corp CVS
- Guardian Pharmacy Services, Inc. GRDN
- 111, Inc. YI
- Ridgetech Inc. RDGT
- TREES Corp (Colorado) CANN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.